nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—ABCB1—ovarian cancer	0.341	1	CbGaD
Dabigatran etexilate—UGT2B7—Epirubicin—ovarian cancer	0.153	0.509	CbGbCtD
Dabigatran etexilate—ABCB1—Topotecan—ovarian cancer	0.0522	0.174	CbGbCtD
Dabigatran etexilate—ABCB1—Vinorelbine—ovarian cancer	0.0368	0.122	CbGbCtD
Dabigatran etexilate—ABCB1—Paclitaxel—ovarian cancer	0.0259	0.086	CbGbCtD
Dabigatran etexilate—ABCB1—Docetaxel—ovarian cancer	0.0187	0.0622	CbGbCtD
Dabigatran etexilate—F2—vein—ovarian cancer	0.0167	0.177	CbGeAlD
Dabigatran etexilate—ABCB1—Doxorubicin—ovarian cancer	0.0139	0.0464	CbGbCtD
Dabigatran etexilate—CES2—myometrium—ovarian cancer	0.00367	0.0387	CbGeAlD
Dabigatran etexilate—UGT2B15—female reproductive system—ovarian cancer	0.0035	0.037	CbGeAlD
Dabigatran etexilate—NQO2—myometrium—ovarian cancer	0.00328	0.0346	CbGeAlD
Dabigatran etexilate—CES2—uterine cervix—ovarian cancer	0.00286	0.0302	CbGeAlD
Dabigatran etexilate—CES2—decidua—ovarian cancer	0.00272	0.0287	CbGeAlD
Dabigatran etexilate—F2—epithelium—ovarian cancer	0.00258	0.0273	CbGeAlD
Dabigatran etexilate—CES2—endometrium—ovarian cancer	0.00258	0.0273	CbGeAlD
Dabigatran etexilate—NQO2—uterine cervix—ovarian cancer	0.00255	0.0269	CbGeAlD
Dabigatran etexilate—NQO2—decidua—ovarian cancer	0.00243	0.0257	CbGeAlD
Dabigatran etexilate—CES2—gonad—ovarian cancer	0.0024	0.0253	CbGeAlD
Dabigatran etexilate—CES2—uterus—ovarian cancer	0.00238	0.0251	CbGeAlD
Dabigatran etexilate—NQO2—endometrium—ovarian cancer	0.00231	0.0244	CbGeAlD
Dabigatran etexilate—UGT2B7—female reproductive system—ovarian cancer	0.00214	0.0226	CbGeAlD
Dabigatran etexilate—CES2—female reproductive system—ovarian cancer	0.00214	0.0226	CbGeAlD
Dabigatran etexilate—NQO2—uterus—ovarian cancer	0.00213	0.0225	CbGeAlD
Dabigatran etexilate—CES2—bone marrow—ovarian cancer	0.00202	0.0213	CbGeAlD
Dabigatran etexilate—CES2—female gonad—ovarian cancer	0.00195	0.0206	CbGeAlD
Dabigatran etexilate—CES2—vagina—ovarian cancer	0.00194	0.0204	CbGeAlD
Dabigatran etexilate—F2—female reproductive system—ovarian cancer	0.00192	0.0203	CbGeAlD
Dabigatran etexilate—NQO2—female reproductive system—ovarian cancer	0.00191	0.0202	CbGeAlD
Dabigatran etexilate—F2—bone marrow—ovarian cancer	0.00181	0.0191	CbGeAlD
Dabigatran etexilate—NQO2—bone marrow—ovarian cancer	0.00181	0.0191	CbGeAlD
Dabigatran etexilate—CES1—female reproductive system—ovarian cancer	0.00176	0.0186	CbGeAlD
Dabigatran etexilate—F2—female gonad—ovarian cancer	0.00175	0.0184	CbGeAlD
Dabigatran etexilate—NQO2—female gonad—ovarian cancer	0.00174	0.0184	CbGeAlD
Dabigatran etexilate—NQO2—vagina—ovarian cancer	0.00173	0.0183	CbGeAlD
Dabigatran etexilate—CES2—testis—ovarian cancer	0.00173	0.0182	CbGeAlD
Dabigatran etexilate—UGT2B7—testis—ovarian cancer	0.00173	0.0182	CbGeAlD
Dabigatran etexilate—CES1—female gonad—ovarian cancer	0.0016	0.0169	CbGeAlD
Dabigatran etexilate—NQO2—testis—ovarian cancer	0.00154	0.0163	CbGeAlD
Dabigatran etexilate—CES1—testis—ovarian cancer	0.00142	0.015	CbGeAlD
Dabigatran etexilate—CES2—lymph node—ovarian cancer	0.00125	0.0132	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—ovarian cancer	0.00112	0.0118	CbGeAlD
Dabigatran etexilate—CES1—lymph node—ovarian cancer	0.00103	0.0109	CbGeAlD
Dabigatran etexilate—ABCB1—myometrium—ovarian cancer	0.000708	0.00747	CbGeAlD
Dabigatran etexilate—ABCB1—embryo—ovarian cancer	0.000681	0.00719	CbGeAlD
Dabigatran etexilate—ABCB1—epithelium—ovarian cancer	0.000556	0.00587	CbGeAlD
Dabigatran etexilate—ABCB1—uterine cervix—ovarian cancer	0.000551	0.00582	CbGeAlD
Dabigatran etexilate—ABCB1—decidua—ovarian cancer	0.000525	0.00554	CbGeAlD
Dabigatran etexilate—ABCB1—endometrium—ovarian cancer	0.000498	0.00526	CbGeAlD
Dabigatran etexilate—ABCB1—gonad—ovarian cancer	0.000462	0.00488	CbGeAlD
Dabigatran etexilate—ABCB1—uterus—ovarian cancer	0.000459	0.00485	CbGeAlD
Dabigatran etexilate—ABCB1—female reproductive system—ovarian cancer	0.000413	0.00436	CbGeAlD
Dabigatran etexilate—ABCB1—bone marrow—ovarian cancer	0.00039	0.00411	CbGeAlD
Dabigatran etexilate—ABCB1—female gonad—ovarian cancer	0.000376	0.00397	CbGeAlD
Dabigatran etexilate—ABCB1—vagina—ovarian cancer	0.000373	0.00394	CbGeAlD
Dabigatran etexilate—ABCB1—testis—ovarian cancer	0.000333	0.00352	CbGeAlD
Dabigatran etexilate—Haemorrhage—Docetaxel—ovarian cancer	0.000276	0.00133	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Epirubicin—ovarian cancer	0.000276	0.00133	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Topotecan—ovarian cancer	0.000275	0.00133	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000275	0.00132	CcSEcCtD
Dabigatran etexilate—Back pain—Paclitaxel—ovarian cancer	0.000274	0.00132	CcSEcCtD
Dabigatran etexilate—Urticaria—Vinorelbine—ovarian cancer	0.000273	0.00132	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Docetaxel—ovarian cancer	0.000273	0.00131	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Vinorelbine—ovarian cancer	0.000272	0.00131	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Docetaxel—ovarian cancer	0.000272	0.00131	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Docetaxel—ovarian cancer	0.000271	0.00131	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Docetaxel—ovarian cancer	0.000271	0.0013	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Melphalan—ovarian cancer	0.00027	0.0013	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Epirubicin—ovarian cancer	0.000269	0.0013	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Epirubicin—ovarian cancer	0.000269	0.0013	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Epirubicin—ovarian cancer	0.000269	0.0013	CcSEcCtD
Dabigatran etexilate—Nausea—Chlorambucil—ovarian cancer	0.000268	0.00129	CcSEcCtD
Dabigatran etexilate—Dizziness—Topotecan—ovarian cancer	0.000266	0.00128	CcSEcCtD
Dabigatran etexilate—Anaemia—Paclitaxel—ovarian cancer	0.000262	0.00126	CcSEcCtD
Dabigatran etexilate—Angioedema—Paclitaxel—ovarian cancer	0.000259	0.00125	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Docetaxel—ovarian cancer	0.000256	0.00123	CcSEcCtD
Dabigatran etexilate—Vomiting—Topotecan—ovarian cancer	0.000256	0.00123	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Doxorubicin—ovarian cancer	0.000255	0.00123	CcSEcCtD
Dabigatran etexilate—Syncope—Paclitaxel—ovarian cancer	0.000254	0.00123	CcSEcCtD
Dabigatran etexilate—Rash—Topotecan—ovarian cancer	0.000254	0.00122	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Vinorelbine—ovarian cancer	0.000254	0.00122	CcSEcCtD
Dabigatran etexilate—Dermatitis—Topotecan—ovarian cancer	0.000253	0.00122	CcSEcCtD
Dabigatran etexilate—Headache—Topotecan—ovarian cancer	0.000252	0.00121	CcSEcCtD
Dabigatran etexilate—Palpitations—Paclitaxel—ovarian cancer	0.000251	0.00121	CcSEcCtD
Dabigatran etexilate—Angiopathy—Docetaxel—ovarian cancer	0.000251	0.00121	CcSEcCtD
Dabigatran etexilate—Vomiting—Melphalan—ovarian cancer	0.000251	0.00121	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Docetaxel—ovarian cancer	0.000249	0.0012	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Paclitaxel—ovarian cancer	0.000249	0.0012	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Doxorubicin—ovarian cancer	0.000249	0.0012	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Doxorubicin—ovarian cancer	0.000249	0.0012	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Doxorubicin—ovarian cancer	0.000249	0.0012	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Docetaxel—ovarian cancer	0.000249	0.0012	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Epirubicin—ovarian cancer	0.000249	0.0012	CcSEcCtD
Dabigatran etexilate—Rash—Melphalan—ovarian cancer	0.000248	0.0012	CcSEcCtD
Dabigatran etexilate—Dermatitis—Melphalan—ovarian cancer	0.000248	0.0012	CcSEcCtD
Dabigatran etexilate—Cough—Paclitaxel—ovarian cancer	0.000248	0.00119	CcSEcCtD
Dabigatran etexilate—Asthenia—Vinorelbine—ovarian cancer	0.000247	0.00119	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Epirubicin—ovarian cancer	0.000246	0.00118	CcSEcCtD
Dabigatran etexilate—Hypertension—Paclitaxel—ovarian cancer	0.000245	0.00118	CcSEcCtD
Dabigatran etexilate—Pruritus—Vinorelbine—ovarian cancer	0.000244	0.00117	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000243	0.00117	CcSEcCtD
Dabigatran etexilate—Arthralgia—Paclitaxel—ovarian cancer	0.000242	0.00116	CcSEcCtD
Dabigatran etexilate—Chest pain—Paclitaxel—ovarian cancer	0.000242	0.00116	CcSEcCtD
Dabigatran etexilate—ABCB1—lymph node—ovarian cancer	0.000241	0.00255	CbGeAlD
Dabigatran etexilate—Nasopharyngitis—Epirubicin—ovarian cancer	0.000241	0.00116	CcSEcCtD
Dabigatran etexilate—Malnutrition—Docetaxel—ovarian cancer	0.00024	0.00116	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00024	0.00116	CcSEcCtD
Dabigatran etexilate—Nausea—Topotecan—ovarian cancer	0.000239	0.00115	CcSEcCtD
Dabigatran etexilate—Gastritis—Epirubicin—ovarian cancer	0.000238	0.00115	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000238	0.00114	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Vinorelbine—ovarian cancer	0.000236	0.00113	CcSEcCtD
Dabigatran etexilate—Nausea—Melphalan—ovarian cancer	0.000234	0.00113	CcSEcCtD
Dabigatran etexilate—Dysphagia—Epirubicin—ovarian cancer	0.000233	0.00112	CcSEcCtD
Dabigatran etexilate—Influenza—Epirubicin—ovarian cancer	0.000233	0.00112	CcSEcCtD
Dabigatran etexilate—Back pain—Docetaxel—ovarian cancer	0.000233	0.00112	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000232	0.00111	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Doxorubicin—ovarian cancer	0.00023	0.00111	CcSEcCtD
Dabigatran etexilate—Infection—Paclitaxel—ovarian cancer	0.00023	0.00111	CcSEcCtD
Dabigatran etexilate—Shock—Paclitaxel—ovarian cancer	0.000228	0.0011	CcSEcCtD
Dabigatran etexilate—Dizziness—Vinorelbine—ovarian cancer	0.000228	0.0011	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000228	0.0011	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Paclitaxel—ovarian cancer	0.000227	0.00109	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Epirubicin—ovarian cancer	0.000227	0.00109	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000227	0.00109	CcSEcCtD
Dabigatran etexilate—Skin disorder—Paclitaxel—ovarian cancer	0.000225	0.00108	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000224	0.00108	CcSEcCtD
Dabigatran etexilate—Bronchitis—Epirubicin—ovarian cancer	0.000224	0.00108	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000223	0.00107	CcSEcCtD
Dabigatran etexilate—Anaemia—Docetaxel—ovarian cancer	0.000222	0.00107	CcSEcCtD
Dabigatran etexilate—Gastritis—Doxorubicin—ovarian cancer	0.000221	0.00106	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.00022	0.00106	CcSEcCtD
Dabigatran etexilate—Vomiting—Vinorelbine—ovarian cancer	0.000219	0.00105	CcSEcCtD
Dabigatran etexilate—Rash—Vinorelbine—ovarian cancer	0.000217	0.00105	CcSEcCtD
Dabigatran etexilate—Dermatitis—Vinorelbine—ovarian cancer	0.000217	0.00104	CcSEcCtD
Dabigatran etexilate—Hypotension—Paclitaxel—ovarian cancer	0.000216	0.00104	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000216	0.00104	CcSEcCtD
Dabigatran etexilate—Headache—Vinorelbine—ovarian cancer	0.000216	0.00104	CcSEcCtD
Dabigatran etexilate—Syncope—Docetaxel—ovarian cancer	0.000216	0.00104	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—ovarian cancer	0.000215	0.00104	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—ovarian cancer	0.000215	0.00104	CcSEcCtD
Dabigatran etexilate—Palpitations—Docetaxel—ovarian cancer	0.000212	0.00102	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Docetaxel—ovarian cancer	0.000211	0.00102	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000211	0.00102	CcSEcCtD
Dabigatran etexilate—Cough—Docetaxel—ovarian cancer	0.00021	0.00101	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Doxorubicin—ovarian cancer	0.00021	0.00101	CcSEcCtD
Dabigatran etexilate—Pneumonia—Epirubicin—ovarian cancer	0.000209	0.00101	CcSEcCtD
Dabigatran etexilate—Hypertension—Docetaxel—ovarian cancer	0.000208	0.001	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Epirubicin—ovarian cancer	0.000208	0.000999	CcSEcCtD
Dabigatran etexilate—Infestation—Epirubicin—ovarian cancer	0.000208	0.000999	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—ovarian cancer	0.000207	0.000997	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Paclitaxel—ovarian cancer	0.000206	0.000994	CcSEcCtD
Dabigatran etexilate—Chest pain—Docetaxel—ovarian cancer	0.000205	0.000986	CcSEcCtD
Dabigatran etexilate—Arthralgia—Docetaxel—ovarian cancer	0.000205	0.000986	CcSEcCtD
Dabigatran etexilate—Nausea—Vinorelbine—ovarian cancer	0.000204	0.000985	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Paclitaxel—ovarian cancer	0.000204	0.000981	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000203	0.000979	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Epirubicin—ovarian cancer	0.000202	0.000971	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.0002	0.000964	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.0002	0.000963	CcSEcCtD
Dabigatran etexilate—Fatigue—Paclitaxel—ovarian cancer	0.0002	0.000961	CcSEcCtD
Dabigatran etexilate—Constipation—Paclitaxel—ovarian cancer	0.000198	0.000953	CcSEcCtD
Dabigatran etexilate—Haematuria—Epirubicin—ovarian cancer	0.000198	0.000953	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000196	0.000945	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Docetaxel—ovarian cancer	0.000196	0.000945	CcSEcCtD
Dabigatran etexilate—Epistaxis—Epirubicin—ovarian cancer	0.000196	0.000943	CcSEcCtD
Dabigatran etexilate—Infection—Docetaxel—ovarian cancer	0.000195	0.000939	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—ovarian cancer	0.000195	0.000938	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—ovarian cancer	0.000193	0.00093	CcSEcCtD
Dabigatran etexilate—Shock—Docetaxel—ovarian cancer	0.000193	0.00093	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Docetaxel—ovarian cancer	0.000192	0.000927	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Docetaxel—ovarian cancer	0.000192	0.000925	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—ovarian cancer	0.000192	0.000925	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—ovarian cancer	0.000192	0.000925	CcSEcCtD
Dabigatran etexilate—Skin disorder—Docetaxel—ovarian cancer	0.000191	0.000918	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000189	0.000912	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—ovarian cancer	0.000187	0.000902	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—ovarian cancer	0.000187	0.000899	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—ovarian cancer	0.000186	0.000897	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—ovarian cancer	0.000184	0.000886	CcSEcCtD
Dabigatran etexilate—Urticaria—Paclitaxel—ovarian cancer	0.000184	0.000886	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—ovarian cancer	0.000184	0.000884	CcSEcCtD
Dabigatran etexilate—Hypotension—Docetaxel—ovarian cancer	0.000183	0.000883	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—ovarian cancer	0.000183	0.000882	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—ovarian cancer	0.000183	0.000882	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Paclitaxel—ovarian cancer	0.000183	0.000881	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—ovarian cancer	0.000183	0.000879	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000182	0.000875	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—ovarian cancer	0.000181	0.000872	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—ovarian cancer	0.00018	0.000868	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000179	0.000861	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Docetaxel—ovarian cancer	0.000175	0.000843	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—ovarian cancer	0.000173	0.000834	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—ovarian cancer	0.000173	0.000833	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Docetaxel—ovarian cancer	0.000173	0.000832	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—ovarian cancer	0.000172	0.00083	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Paclitaxel—ovarian cancer	0.000171	0.000821	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—ovarian cancer	0.00017	0.00082	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—ovarian cancer	0.00017	0.000818	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000169	0.000816	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000169	0.000816	CcSEcCtD
Dabigatran etexilate—Fatigue—Docetaxel—ovarian cancer	0.000169	0.000815	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—ovarian cancer	0.000169	0.000814	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—ovarian cancer	0.000169	0.000814	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Epirubicin—ovarian cancer	0.000168	0.00081	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—ovarian cancer	0.000168	0.000809	CcSEcCtD
Dabigatran etexilate—Constipation—Docetaxel—ovarian cancer	0.000168	0.000808	CcSEcCtD
Dabigatran etexilate—Asthenia—Paclitaxel—ovarian cancer	0.000166	0.0008	CcSEcCtD
Dabigatran etexilate—Pruritus—Paclitaxel—ovarian cancer	0.000164	0.000789	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—ovarian cancer	0.000162	0.000781	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00016	0.000773	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—ovarian cancer	0.00016	0.00077	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—ovarian cancer	0.00016	0.00077	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Paclitaxel—ovarian cancer	0.000158	0.000763	CcSEcCtD
Dabigatran etexilate—Back pain—Epirubicin—ovarian cancer	0.000157	0.000755	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—ovarian cancer	0.000156	0.000753	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—ovarian cancer	0.000156	0.00075	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000155	0.000748	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Docetaxel—ovarian cancer	0.000155	0.000747	CcSEcCtD
Dabigatran etexilate—Dizziness—Paclitaxel—ovarian cancer	0.000153	0.000737	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—ovarian cancer	0.00015	0.000723	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—ovarian cancer	0.00015	0.000722	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—ovarian cancer	0.000148	0.000712	CcSEcCtD
Dabigatran etexilate—Vomiting—Paclitaxel—ovarian cancer	0.000147	0.000709	CcSEcCtD
Dabigatran etexilate—Rash—Paclitaxel—ovarian cancer	0.000146	0.000703	CcSEcCtD
Dabigatran etexilate—Dermatitis—Paclitaxel—ovarian cancer	0.000146	0.000702	CcSEcCtD
Dabigatran etexilate—Syncope—Epirubicin—ovarian cancer	0.000145	0.0007	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—ovarian cancer	0.000145	0.000699	CcSEcCtD
Dabigatran etexilate—Headache—Paclitaxel—ovarian cancer	0.000145	0.000698	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Docetaxel—ovarian cancer	0.000145	0.000696	CcSEcCtD
Dabigatran etexilate—Palpitations—Epirubicin—ovarian cancer	0.000143	0.00069	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Epirubicin—ovarian cancer	0.000143	0.000686	CcSEcCtD
Dabigatran etexilate—Cough—Epirubicin—ovarian cancer	0.000142	0.000682	CcSEcCtD
Dabigatran etexilate—Asthenia—Docetaxel—ovarian cancer	0.000141	0.000678	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—ovarian cancer	0.00014	0.000674	CcSEcCtD
Dabigatran etexilate—Pruritus—Docetaxel—ovarian cancer	0.000139	0.000669	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—ovarian cancer	0.000139	0.000668	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—ovarian cancer	0.000138	0.000665	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—ovarian cancer	0.000138	0.000665	CcSEcCtD
Dabigatran etexilate—Nausea—Paclitaxel—ovarian cancer	0.000138	0.000662	CcSEcCtD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	0.000137	0.00246	CbGpPWpGaD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000137	0.00066	CcSEcCtD
Dabigatran etexilate—Syncope—Doxorubicin—ovarian cancer	0.000135	0.000648	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Docetaxel—ovarian cancer	0.000134	0.000647	CcSEcCtD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—AKT1—ovarian cancer	0.000133	0.00238	CbGpPWpGaD
Dabigatran etexilate—Palpitations—Doxorubicin—ovarian cancer	0.000133	0.000639	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—ovarian cancer	0.000132	0.000637	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—ovarian cancer	0.000132	0.000635	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—ovarian cancer	0.000131	0.000633	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CG—ovarian cancer	0.000131	0.00236	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—APC—ovarian cancer	0.000131	0.00236	CbGpPWpGaD
Dabigatran etexilate—Cough—Doxorubicin—ovarian cancer	0.000131	0.000631	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—ovarian cancer	0.00013	0.000627	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—ovarian cancer	0.00013	0.000625	CcSEcCtD
Dabigatran etexilate—Dizziness—Docetaxel—ovarian cancer	0.00013	0.000625	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—ovarian cancer	0.00013	0.000624	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—ovarian cancer	0.00013	0.000624	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—ovarian cancer	0.000129	0.000619	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IL6—ovarian cancer	0.000128	0.0023	CbGpPWpGaD
Dabigatran etexilate—Chest pain—Doxorubicin—ovarian cancer	0.000128	0.000615	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—ovarian cancer	0.000128	0.000615	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000127	0.000611	CcSEcCtD
Dabigatran etexilate—Vomiting—Docetaxel—ovarian cancer	0.000125	0.000601	CcSEcCtD
Dabigatran etexilate—Rash—Docetaxel—ovarian cancer	0.000124	0.000596	CcSEcCtD
Dabigatran etexilate—Hypotension—Epirubicin—ovarian cancer	0.000124	0.000596	CcSEcCtD
Dabigatran etexilate—Dermatitis—Docetaxel—ovarian cancer	0.000124	0.000595	CcSEcCtD
Dabigatran etexilate—Headache—Docetaxel—ovarian cancer	0.000123	0.000592	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000122	0.00059	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—ovarian cancer	0.000122	0.000586	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000121	0.000581	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—ovarian cancer	0.00012	0.00058	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—AKT1—ovarian cancer	0.00012	0.00215	CbGpPWpGaD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—ovarian cancer	0.00012	0.000578	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—ovarian cancer	0.00012	0.000577	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—ovarian cancer	0.000119	0.000573	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Epirubicin—ovarian cancer	0.000118	0.000568	CcSEcCtD
Dabigatran etexilate—Nausea—Docetaxel—ovarian cancer	0.000117	0.000561	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—ovarian cancer	0.000117	0.000561	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CD—ovarian cancer	0.000116	0.00207	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000115	0.00207	CbGpPWpGaD
Dabigatran etexilate—Hypotension—Doxorubicin—ovarian cancer	0.000114	0.000551	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000114	0.00055	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—ovarian cancer	0.000114	0.00055	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—TP53—ovarian cancer	0.000114	0.00204	CbGpPWpGaD
Dabigatran etexilate—Constipation—Epirubicin—ovarian cancer	0.000113	0.000545	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—NME2—ovarian cancer	0.000112	0.00201	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000112	0.000537	CcSEcCtD
Dabigatran etexilate—F2—Signaling Pathways—HSD17B6—ovarian cancer	0.00011	0.00197	CbGpPWpGaD
Dabigatran etexilate—Dyspnoea—Doxorubicin—ovarian cancer	0.000109	0.000526	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000108	0.000521	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Doxorubicin—ovarian cancer	0.000108	0.000519	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—NRAS—ovarian cancer	0.000108	0.00193	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—TUBB3—ovarian cancer	0.000106	0.0019	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000106	0.000509	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—ovarian cancer	0.000106	0.000508	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—ovarian cancer	0.000105	0.000506	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—ovarian cancer	0.000105	0.000504	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—ovarian cancer	0.000105	0.000504	CcSEcCtD
Dabigatran etexilate—F2—Folate Metabolism—IL6—ovarian cancer	0.000104	0.00187	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—TERT—ovarian cancer	0.000104	0.00186	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SPARC—ovarian cancer	0.000102	0.00183	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	0.000102	0.00183	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CB—ovarian cancer	0.000101	0.0018	CbGpPWpGaD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.0001	0.000482	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Epirubicin—ovarian cancer	9.75e-05	0.00047	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—ovarian cancer	9.73e-05	0.000469	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—ovarian cancer	9.68e-05	0.000466	CcSEcCtD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CG—ovarian cancer	9.59e-05	0.00172	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Epirubicin—ovarian cancer	9.5e-05	0.000457	CcSEcCtD
Dabigatran etexilate—Pruritus—Epirubicin—ovarian cancer	9.36e-05	0.000451	CcSEcCtD
Dabigatran etexilate—F2—Signaling Pathways—DLC1—ovarian cancer	9.36e-05	0.00168	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—YAP1—ovarian cancer	9.31e-05	0.00167	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—KRAS—ovarian cancer	9.27e-05	0.00166	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NME2—ovarian cancer	9.12e-05	0.00163	CbGpPWpGaD
Dabigatran etexilate—Diarrhoea—Epirubicin—ovarian cancer	9.06e-05	0.000436	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—ovarian cancer	9.02e-05	0.000435	CcSEcCtD
Dabigatran etexilate—F2—Metabolism of proteins—ATF3—ovarian cancer	8.95e-05	0.0016	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Doxorubicin—ovarian cancer	8.79e-05	0.000423	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—ovarian cancer	8.75e-05	0.000421	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—ovarian cancer	8.66e-05	0.000417	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—PIK3CA—ovarian cancer	8.52e-05	0.00153	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CD—ovarian cancer	8.43e-05	0.00151	CbGpPWpGaD
Dabigatran etexilate—Vomiting—Epirubicin—ovarian cancer	8.42e-05	0.000405	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—ovarian cancer	8.38e-05	0.000404	CcSEcCtD
Dabigatran etexilate—Rash—Epirubicin—ovarian cancer	8.35e-05	0.000402	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—ovarian cancer	8.34e-05	0.000402	CcSEcCtD
Dabigatran etexilate—Headache—Epirubicin—ovarian cancer	8.29e-05	0.000399	CcSEcCtD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IL6—ovarian cancer	8.29e-05	0.00148	CbGpPWpGaD
Dabigatran etexilate—Dizziness—Doxorubicin—ovarian cancer	8.1e-05	0.00039	CcSEcCtD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ovarian cancer	8e-05	0.00143	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CXCL8—ovarian cancer	7.97e-05	0.00143	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—HRAS—ovarian cancer	7.88e-05	0.00141	CbGpPWpGaD
Dabigatran etexilate—Nausea—Epirubicin—ovarian cancer	7.86e-05	0.000379	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—ovarian cancer	7.79e-05	0.000375	CcSEcCtD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—NRAS—ovarian cancer	7.77e-05	0.00139	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	7.74e-05	0.00139	CbGpPWpGaD
Dabigatran etexilate—Rash—Doxorubicin—ovarian cancer	7.72e-05	0.000372	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—ovarian cancer	7.71e-05	0.000372	CcSEcCtD
Dabigatran etexilate—Headache—Doxorubicin—ovarian cancer	7.67e-05	0.000369	CcSEcCtD
Dabigatran etexilate—F2—Signaling Pathways—BCL9—ovarian cancer	7.63e-05	0.00137	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—FASN—ovarian cancer	7.59e-05	0.00136	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SLC5A5—ovarian cancer	7.47e-05	0.00134	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—MAPK3—ovarian cancer	7.44e-05	0.00133	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SOD1—ovarian cancer	7.42e-05	0.00133	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PPP2R1A—ovarian cancer	7.38e-05	0.00132	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CB—ovarian cancer	7.35e-05	0.00132	CbGpPWpGaD
Dabigatran etexilate—Nausea—Doxorubicin—ovarian cancer	7.27e-05	0.00035	CcSEcCtD
Dabigatran etexilate—UGT2B7—Metabolism—CYTB—ovarian cancer	7.23e-05	0.0013	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—SLC2A1—ovarian cancer	7.21e-05	0.00129	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—MAPK1—ovarian cancer	7.08e-05	0.00127	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—EGFR—ovarian cancer	7.07e-05	0.00127	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	6.93e-05	0.00124	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP1B1—ovarian cancer	6.91e-05	0.00124	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IL2—ovarian cancer	6.75e-05	0.00121	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—KRAS—ovarian cancer	6.68e-05	0.0012	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	6.33e-05	0.00113	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—BRIP1—ovarian cancer	6.32e-05	0.00113	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPP1CC—ovarian cancer	6.32e-05	0.00113	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	6.31e-05	0.00113	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CA—ovarian cancer	6.14e-05	0.0011	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPP2R1A—ovarian cancer	6.13e-05	0.0011	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ovarian cancer	6.12e-05	0.0011	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—DOK1—ovarian cancer	6.03e-05	0.00108	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	5.93e-05	0.00106	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYTB—ovarian cancer	5.88e-05	0.00105	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	5.79e-05	0.00104	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	5.75e-05	0.00103	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	5.73e-05	0.00103	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ABCB1—ovarian cancer	5.69e-05	0.00102	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PPP1CC—ovarian cancer	5.67e-05	0.00102	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—TYMS—ovarian cancer	5.59e-05	0.001	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CXCL8—ovarian cancer	5.59e-05	0.001	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	5.55e-05	0.000994	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—CAV1—ovarian cancer	5.43e-05	0.000972	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	5.43e-05	0.000972	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	5.37e-05	0.000962	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—AQP3—ovarian cancer	5.35e-05	0.000959	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CASP3—ovarian cancer	5.35e-05	0.000959	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	5.35e-05	0.000958	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2—ovarian cancer	5.34e-05	0.000957	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	5.28e-05	0.000945	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	5.28e-05	0.000945	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	5.24e-05	0.000939	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	5.2e-05	0.000931	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	5.16e-05	0.000925	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—BRIP1—ovarian cancer	5.14e-05	0.000921	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPP1CC—ovarian cancer	5.14e-05	0.000921	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ATP7B—ovarian cancer	5.13e-05	0.000919	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—PIK3CA—ovarian cancer	5.12e-05	0.000917	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	5.1e-05	0.000915	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	4.98e-05	0.000893	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CG—ovarian cancer	4.94e-05	0.000886	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	4.58e-05	0.00082	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—ovarian cancer	4.54e-05	0.000814	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CAV1—ovarian cancer	4.51e-05	0.000807	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	4.48e-05	0.000803	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CD—ovarian cancer	4.35e-05	0.000779	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HDAC6—ovarian cancer	4.3e-05	0.00077	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—YAP1—ovarian cancer	4.24e-05	0.00076	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PPP2R1A—ovarian cancer	4.24e-05	0.000759	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	4.24e-05	0.000759	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NME2—ovarian cancer	4.18e-05	0.00075	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CG—ovarian cancer	4.1e-05	0.000735	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCL8—ovarian cancer	4.07e-05	0.000729	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—TUBB3—ovarian cancer	4.06e-05	0.000727	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	4.05e-05	0.000726	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	3.96e-05	0.00071	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—YAP1—ovarian cancer	3.8e-05	0.000681	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CB—ovarian cancer	3.79e-05	0.000679	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	3.75e-05	0.000671	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.74e-05	0.000671	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—XIAP—ovarian cancer	3.72e-05	0.000667	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	3.66e-05	0.000656	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SMARCA4—ovarian cancer	3.63e-05	0.00065	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CD—ovarian cancer	3.61e-05	0.000646	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EREG—ovarian cancer	3.54e-05	0.000635	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2—ovarian cancer	3.48e-05	0.000623	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—FASN—ovarian cancer	3.46e-05	0.000619	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—YAP1—ovarian cancer	3.45e-05	0.000617	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MMP2—ovarian cancer	3.45e-05	0.000617	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.41e-05	0.000611	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC5A5—ovarian cancer	3.4e-05	0.000609	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	3.35e-05	0.000599	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PGR—ovarian cancer	3.32e-05	0.000595	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—SLC2A1—ovarian cancer	3.28e-05	0.000588	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP1B1—ovarian cancer	3.15e-05	0.000564	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CB—ovarian cancer	3.14e-05	0.000563	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CG—ovarian cancer	3.12e-05	0.00056	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PARP1—ovarian cancer	3.09e-05	0.000553	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3e-05	0.000537	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—ovarian cancer	2.96e-05	0.00053	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6ST—ovarian cancer	2.95e-05	0.000529	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NRAS—ovarian cancer	2.92e-05	0.000523	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	2.91e-05	0.000521	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CXCL8—ovarian cancer	2.86e-05	0.000513	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CG—ovarian cancer	2.84e-05	0.000508	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—FASN—ovarian cancer	2.81e-05	0.000503	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MAPK3—ovarian cancer	2.8e-05	0.000501	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPP2R1A—ovarian cancer	2.79e-05	0.0005	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC5A5—ovarian cancer	2.76e-05	0.000495	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CD—ovarian cancer	2.75e-05	0.000492	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTEN—ovarian cancer	2.72e-05	0.000487	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.71e-05	0.000485	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYTB—ovarian cancer	2.7e-05	0.000483	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	2.69e-05	0.000483	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SLC2A1—ovarian cancer	2.67e-05	0.000478	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MAPK1—ovarian cancer	2.66e-05	0.000477	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—ovarian cancer	2.64e-05	0.000473	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	2.64e-05	0.000473	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.61e-05	0.000468	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.61e-05	0.000468	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ABCB1—ovarian cancer	2.59e-05	0.000465	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	2.57e-05	0.00046	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP1B1—ovarian cancer	2.56e-05	0.000458	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—TYMS—ovarian cancer	2.55e-05	0.000456	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	2.55e-05	0.000456	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—ovarian cancer	2.51e-05	0.00045	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PPP2R1A—ovarian cancer	2.5e-05	0.000449	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CD—ovarian cancer	2.49e-05	0.000447	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	2.48e-05	0.000444	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CB—ovarian cancer	2.39e-05	0.000429	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPP1CC—ovarian cancer	2.36e-05	0.000422	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—BRIP1—ovarian cancer	2.36e-05	0.000422	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—ovarian cancer	2.31e-05	0.000414	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCL8—ovarian cancer	2.3e-05	0.000412	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPP2R1A—ovarian cancer	2.27e-05	0.000407	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.26e-05	0.000405	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	2.24e-05	0.000401	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—ovarian cancer	2.23e-05	0.0004	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—ovarian cancer	2.2e-05	0.000394	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CB—ovarian cancer	2.17e-05	0.000389	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—ovarian cancer	2.14e-05	0.000383	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	2.12e-05	0.00038	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCB1—ovarian cancer	2.11e-05	0.000378	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCL8—ovarian cancer	2.09e-05	0.000374	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—TYMS—ovarian cancer	2.07e-05	0.000371	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	2.06e-05	0.000369	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CAV1—ovarian cancer	2.05e-05	0.000368	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	2.02e-05	0.000361	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	2.02e-05	0.000361	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—ovarian cancer	2e-05	0.000358	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—ovarian cancer	1.99e-05	0.000356	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—ovarian cancer	1.92e-05	0.000343	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	1.9e-05	0.000341	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—ovarian cancer	1.89e-05	0.000338	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CG—ovarian cancer	1.87e-05	0.000335	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CAV1—ovarian cancer	1.84e-05	0.00033	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ESR1—ovarian cancer	1.77e-05	0.000318	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	1.75e-05	0.000314	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6ST—ovarian cancer	1.74e-05	0.000312	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.69e-05	0.000303	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CG—ovarian cancer	1.68e-05	0.0003	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APC—ovarian cancer	1.68e-05	0.0003	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—NRAS—ovarian cancer	1.68e-05	0.0003	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CAV1—ovarian cancer	1.67e-05	0.000299	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CD—ovarian cancer	1.64e-05	0.000294	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAPK3—ovarian cancer	1.6e-05	0.000288	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.59e-05	0.000285	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—YAP1—ovarian cancer	1.58e-05	0.000283	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—ovarian cancer	1.57e-05	0.000281	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAPK1—ovarian cancer	1.53e-05	0.000274	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—ovarian cancer	1.53e-05	0.000274	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CG—ovarian cancer	1.52e-05	0.000272	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CD—ovarian cancer	1.47e-05	0.000264	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—ovarian cancer	1.46e-05	0.000261	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—ovarian cancer	1.44e-05	0.000258	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CB—ovarian cancer	1.43e-05	0.000257	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.43e-05	0.000256	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CD—ovarian cancer	1.34e-05	0.000239	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—ovarian cancer	1.33e-05	0.000237	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ERBB2—ovarian cancer	1.3e-05	0.000233	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—FASN—ovarian cancer	1.29e-05	0.000231	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MTOR—ovarian cancer	1.28e-05	0.00023	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CB—ovarian cancer	1.28e-05	0.00023	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.27e-05	0.000227	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTEN—ovarian cancer	1.24e-05	0.000222	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCL8—ovarian cancer	1.23e-05	0.000221	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—ovarian cancer	1.23e-05	0.00022	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC2A1—ovarian cancer	1.22e-05	0.000219	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1B—ovarian cancer	1.21e-05	0.000216	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—ovarian cancer	1.19e-05	0.000214	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—ovarian cancer	1.18e-05	0.000212	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—ovarian cancer	1.18e-05	0.000211	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP1B1—ovarian cancer	1.17e-05	0.00021	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—ovarian cancer	1.17e-05	0.00021	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CB—ovarian cancer	1.16e-05	0.000209	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—ovarian cancer	1.15e-05	0.000206	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—ovarian cancer	1.14e-05	0.000204	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—ovarian cancer	1.12e-05	0.0002	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTEN—ovarian cancer	1.11e-05	0.000199	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—ovarian cancer	1.08e-05	0.000194	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPP2R1A—ovarian cancer	1.04e-05	0.000187	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTEN—ovarian cancer	1.01e-05	0.00018	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—ovarian cancer	1e-05	0.00018	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—ovarian cancer	9.92e-06	0.000178	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRAS—ovarian cancer	9.9e-06	0.000177	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TYMS—ovarian cancer	9.49e-06	0.00017	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK3—ovarian cancer	9.48e-06	0.00017	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—ovarian cancer	9.22e-06	0.000165	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK1—ovarian cancer	9.02e-06	0.000162	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—ovarian cancer	9.02e-06	0.000162	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—ovarian cancer	8.73e-06	0.000156	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—ovarian cancer	8.52e-06	0.000153	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—ovarian cancer	7.83e-06	0.00014	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CAV1—ovarian cancer	7.65e-06	0.000137	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—ovarian cancer	7.57e-06	0.000136	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—ovarian cancer	7.24e-06	0.00013	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—ovarian cancer	7.13e-06	0.000128	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—ovarian cancer	7.09e-06	0.000127	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CG—ovarian cancer	6.97e-06	0.000125	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—ovarian cancer	6.93e-06	0.000124	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—ovarian cancer	6.39e-06	0.000115	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CD—ovarian cancer	6.13e-06	0.00011	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—ovarian cancer	5.8e-06	0.000104	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CB—ovarian cancer	5.34e-06	9.57e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTEN—ovarian cancer	4.61e-06	8.27e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—ovarian cancer	3.25e-06	5.83e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—ovarian cancer	2.66e-06	4.76e-05	CbGpPWpGaD
